NFE2L2 and cancer: Due to the dual role of Nrf2 (pro-oncogenic and anti-oncogenic) in cancer patients, other factors, such as metabolic genes, proliferative genes, and angiogenesis genes, should also be considered for inhibiting Nrf2 through Nrf2 inhibitors (Almeida et al., 2020; Smolková et al., 2020; Aliyev et al., 2021).